DK1711530T3 - Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme - Google Patents

Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme

Info

Publication number
DK1711530T3
DK1711530T3 DK04806128T DK04806128T DK1711530T3 DK 1711530 T3 DK1711530 T3 DK 1711530T3 DK 04806128 T DK04806128 T DK 04806128T DK 04806128 T DK04806128 T DK 04806128T DK 1711530 T3 DK1711530 T3 DK 1711530T3
Authority
DK
Denmark
Prior art keywords
nogo
treatment
neurological disorders
neutralizing immunoglobulins
immunoglobulins
Prior art date
Application number
DK04806128T
Other languages
Danish (da)
English (en)
Inventor
Jonathan Henry Ellis
Farhana Hussain
Ruth Mcadam
Christopher Plumpton
Rabinder Kumar Prinjha
Paul Alexander Wilson
Alexandre Eon-Duval
Robert Ian Grundy
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329711A external-priority patent/GB0329711D0/en
Priority claimed from GB0329684A external-priority patent/GB0329684D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1711530T3 publication Critical patent/DK1711530T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04806128T 2003-12-22 2004-12-20 Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme DK1711530T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0329711A GB0329711D0 (en) 2003-12-22 2003-12-22 Antibodies
GB0329684A GB0329684D0 (en) 2003-12-22 2003-12-22 Method
PCT/GB2004/005325 WO2005061544A2 (en) 2003-12-22 2004-12-20 Nogo-a neutralising immunoglobulins for treatment of neurological diseases

Publications (1)

Publication Number Publication Date
DK1711530T3 true DK1711530T3 (da) 2009-12-14

Family

ID=34712703

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04806128T DK1711530T3 (da) 2003-12-22 2004-12-20 Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme

Country Status (28)

Country Link
US (4) US7988964B2 (ru)
EP (3) EP1711530B1 (ru)
JP (2) JP2007537145A (ru)
KR (1) KR101150548B1 (ru)
AR (1) AR048912A1 (ru)
AT (1) ATE440866T1 (ru)
AU (1) AU2004303585B2 (ru)
BR (1) BRPI0417959A (ru)
CA (1) CA2549956C (ru)
CY (1) CY1110530T1 (ru)
DE (1) DE602004022871D1 (ru)
DK (1) DK1711530T3 (ru)
ES (1) ES2330444T3 (ru)
HK (1) HK1100144A1 (ru)
HR (1) HRP20090527T1 (ru)
IL (1) IL176206A (ru)
IS (1) IS2739B (ru)
MA (1) MA28289A1 (ru)
MX (1) MXPA06007190A (ru)
MY (1) MY144612A (ru)
NO (1) NO20062767L (ru)
NZ (1) NZ548013A (ru)
PL (1) PL1711530T3 (ru)
PT (1) PT1711530E (ru)
RU (1) RU2362780C2 (ru)
SI (1) SI1711530T1 (ru)
TW (1) TWI329649B (ru)
WO (2) WO2005061544A2 (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
PL1711530T3 (pl) 2003-12-22 2010-01-29 Glaxo Group Ltd Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych
AU2006265276B2 (en) * 2005-07-05 2011-10-13 Glaxo Group Limited Humanised antibodies specific for NOGO-A and pharmaceutical uses thereof
CA2624562A1 (en) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
GB0525662D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
WO2008002594A2 (en) * 2006-06-27 2008-01-03 Neuroprotection For Life Corp. Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CA2672120A1 (en) * 2006-12-07 2008-06-12 Novartis Ag Antagonistic antibodies against ephb3
EP2486928A1 (en) * 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2009026117A2 (en) * 2007-08-16 2009-02-26 Glaxo Group Limited Novel compounds
AU2008317724B2 (en) 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
KR20100132998A (ko) * 2008-04-04 2010-12-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 종양 성장, 혈관신생 및 전이를 차단하는 것을 목표로 하는 암에 대한 항체
CA2730473A1 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
US9175075B2 (en) 2009-12-08 2015-11-03 AbbVie Deutschland GmbH & Co. KG Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
AU2011315920B2 (en) * 2010-10-15 2016-04-28 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
WO2012058592A2 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Non-antagonistic egfr-binding molecules and immunoconjugates thereof
WO2012058588A2 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
SG11201402343SA (en) 2011-11-21 2014-06-27 Immunogen Inc Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
SG10202006762PA (en) 2012-01-27 2020-08-28 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
BR112014032987A2 (pt) 2012-07-05 2017-06-27 Glaxo Group Ltd método de tratamento ou profilaxia de um distúrbio neurológico
PT3292150T (pt) 2015-05-04 2020-06-01 Cytomx Therapeutics Inc Anticorpos anti-cd166 ativáveis e os seus métodos de utilização
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
EP3652210A1 (en) * 2017-07-14 2020-05-20 CytomX Therapeutics, Inc. Anti-cd166 antibodies and uses thereof
WO2020068058A1 (en) * 2018-09-25 2020-04-02 Academia Sinica Anti-siglec antibody, pharmaceutical composition comprising the same, and uses thereof
EP4048692A2 (en) 2019-10-24 2022-08-31 NovaGo Therapeutics AG Novel anti-nogo-a antibodies
CN116635718A (zh) * 2020-12-02 2023-08-22 安捷伦科技有限公司 用于在免疫组织化学（ihc）方案中使用以诊断癌症的抗人cd10抗体
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
HU226535B1 (en) 1994-05-27 2009-03-30 Glaxosmithkline Spa Quinoline derivatives as tachykinin nk3 receptor antagonists, pharmaceutical compositions containing them, and their use
AU774367C (en) * 1998-11-06 2005-04-21 University Of Zurich Nucleotide and protein sequences of nogo genes and methods based thereon
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
US20030113891A1 (en) * 2000-02-11 2003-06-19 Lawrence Blatt Method and reagent for the inhibition of NOGO and NOGO receptor genes
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
CA2482589A1 (en) * 2002-04-17 2003-10-30 Pharmacia & Upjohn Company Llc Compositions and method of treating alzheimer's disease
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
JP2006523708A (ja) * 2003-04-16 2006-10-19 イェール ユニバーシティ アミロイド斑に関連する状態の処置のためのＮｏｇｏレセプターアンタゴニスト
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
PL1711530T3 (pl) 2003-12-22 2010-01-29 Glaxo Group Ltd Immunoglobuliny neutralizujące Nogo-A do leczenia chorób neurologicznych

Also Published As

Publication number Publication date
IS8506A (is) 2006-06-12
NZ548013A (en) 2009-04-30
PT1711530E (pt) 2009-10-22
TW200533680A (en) 2005-10-16
MXPA06007190A (es) 2006-08-23
MY144612A (en) 2011-10-14
ATE440866T1 (de) 2009-09-15
WO2005061545A2 (en) 2005-07-07
US20070065430A1 (en) 2007-03-22
AR048912A1 (es) 2006-06-14
HRP20090527T1 (en) 2009-11-30
PL1711530T3 (pl) 2010-01-29
IL176206A (en) 2012-02-29
AU2004303585B2 (en) 2010-12-23
SI1711530T1 (sl) 2010-01-29
MA28289A1 (fr) 2006-11-01
TWI329649B (en) 2010-09-01
JP4901480B2 (ja) 2012-03-21
EP2213684A3 (en) 2011-05-18
EP1711530B1 (en) 2009-08-26
EP1711530A2 (en) 2006-10-18
IS2739B (is) 2011-06-15
ES2330444T3 (es) 2009-12-10
IL176206A0 (en) 2006-10-05
WO2005061544A3 (en) 2005-08-18
RU2006123481A (ru) 2008-01-27
US20110054149A1 (en) 2011-03-03
EP1706426A2 (en) 2006-10-04
EP2213684A2 (en) 2010-08-04
JP2008504220A (ja) 2008-02-14
BRPI0417959A (pt) 2007-03-27
NO20062767L (no) 2006-09-20
CY1110530T1 (el) 2015-04-29
WO2005061544A2 (en) 2005-07-07
DE602004022871D1 (de) 2009-10-08
WO2005061545A3 (en) 2005-08-18
AU2004303585A1 (en) 2005-07-07
US20060029603A1 (en) 2006-02-09
RU2362780C2 (ru) 2009-07-27
US20140147435A1 (en) 2014-05-29
KR101150548B1 (ko) 2012-07-06
CA2549956C (en) 2016-04-12
US7780964B2 (en) 2010-08-24
HK1100144A1 (en) 2007-09-07
JP2007537145A (ja) 2007-12-20
US7988964B2 (en) 2011-08-02
KR20060129290A (ko) 2006-12-15
CA2549956A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
DK1711530T3 (da) Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1730119T3 (da) Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
DK1716162T3 (da) Phosphonater, amidomonophosphonater, amidobisphosphonater til behandling af virussygdomme
DK1660057T3 (da) Kombinationsterapi til behandling af neovaskulære øjenlidelser
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
DK1575597T3 (da) Anvendelse af rimexolon til behandling af öjentörhed
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
IS7941A (is) Bensasepínafleiður til að meðhöndla taugasjúkdóma
DK1708991T3 (da) Sulfonamid derivater til behandling af sygdomme
DK2821085T3 (da) Rna-interferens til behandling af "gain-of-function"-forstyrrelser
NO20052223D0 (no) Tiazolforbindelser for behandling av neurodegenerative forstyrrelser
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1643998T3 (da) NK1/NK3-antagonister til behandling af skizofreni
DK1765355T3 (da) Benzoxazin til behandling af luftvejslidelser
NL1030418A1 (nl) Azabenzoxazolen voor de behandeling van CZS-stoornissen.
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
DK1592384T3 (da) Cop 1 til behandling af inflammatoriske tarmsygdomme
DK1841433T3 (da) Præparat til behandling af lidelser i centralnervesystemet
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
NL1026203A1 (nl) Verbindingen toepasbaar voor de behandeling van ziekten.